Maze Therapeutics (MAZE) Change in Receivables (2026)

Maze Therapeutics (MAZE) posted Change in Receivables of $20.0 million for Q1 2026.

Maze Therapeutics (MAZE) Change in Receivables (2026) Analysis & Trends

Maze Therapeutics has reported Change in Receivables for 1 years, with the latest figure at $20.0 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 117.58 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -483,662.49
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 31.60 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 37.16 Mn
10 Maze Therapeutics 1.51 Bn 1.51 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 20.00 Mn
Mar 31, 2026 20.00 Mn